ponatinib,asciminib
takeda,incyte,otsuka,novartis
['cml', 'ponatinib', 'asciminib']
data from nikola u k confirm that combination treatment with asciminib and ponatinib is the most attractive combination strategy for #cml high risk pts. #eha23 
Hematologo en Hospital Universitario Ramon y Cajal @HematoRyC Profesor asociado Universidad de Alcalá. Granaino, marido y padre en Madrid #CML #MPN #HRyC @UAHes